Skip to content
Prices at 18:44
ChartsView
  1. Research
  2. Company trackers
  3. Stryker

Stryker tracker

What Stryker is building, from Mako surgical robots to new joints and clot removal devices, plus its sales by business quarter by quarter, results and the latest news.

SYK Stryker Corporation, listed on NYSE Updated 39 min ago

Sales, Jul–Sep 2026$6.52bnUp 8% on a year earlier. Q3 2026 in Stryker’s own calendar
MedSurg and Neurotechnology sales, Jul–Sep 2026$3.66bnUp 9% on a year earlier. 56% of all sales

Sales by business

Stryker has two businesses. MedSurg and Neurotechnology covers hospital equipment, surgical tools, endoscopy, clot removal and brain surgery. Orthopaedics covers joint replacements, trauma implants and the Mako robot.

Jul–Sep 2026

  • MedSurg and Neurotechnology+9.2% on a year ago$3.66bn56%
  • Orthopaedics+5.7% on a year ago$2.86bn44%

The last five quarters

Q2 2025Apr–Jun 2025Q3 2025Jul–Sep 2025Q1 2026Jan–Mar 2026Q2 2026Apr–Jun 2026Q3 2026Jul–Sep 2026
MedSurg and Neurotechnology$3.31bn$3.36bn$3.21bn$3.63bn$3.66bn
Orthopaedics$2.72bn$2.70bn$2.81bn$2.96bn$2.86bn

Stryker moved some businesses between the two in 2026 and restated past quarters. It has not filed the new split for Oct–Dec 2025, so that quarter is missing. Sources: Q2 2025, Q3 2025, Q1 2026, Q2 2026, Q3 2026

Q3 2026 results

Published 29 Oct 2026. Sales rose 7.7% to $6.52bn, which Stryker said was below its own hopes. Net earnings fell 12% to $753m because of one-off charges; adjusted earnings per share rose 10% to $3.52. It narrowed its 2026 forecast.

In brief

  • Sales of $6.52bn, up 7.7%, driven by selling more units.
  • MedSurg and Neurotechnology sales rose 9.2% to $3.66bn; Orthopaedics rose 5.7% to $2.86bn.
  • Endoscopy grew 14% and Vascular 8%; knees grew 1% and hips fell 1%.
  • Net earnings of $753m, down 12%, after one-off charges. Adjusted earnings per share rose 10% to $3.52.
  • Bought back $1.0bn of its own shares and added $3.0bn to the buyback plan.
  • Now expects 2026 underlying sales growth of 6.5% to 7.0% and adjusted earnings per share of $14.80 to $14.90.
  • Kevin Lobo hands over as chief executive to Spencer Stiles on 1 Jan 2027 (announced 6 Oct).

Against a year ago (Q3 2025)

Q3 2025Q3 2026Change
Sales$6.06bn$6.52bnup +7.6%
MedSurg and Neurotechnology$3.36bn$3.66bnup +9.2%
Orthopaedics$2.70bn$2.86bnup +5.7%
Net earnings$859m$753mdown −12%

Red and green show whether a change is good or bad for Stryker, so more spending shows in red.

Sales

Sales by quarter
  1. $6.1bn
  2. $7.2bn
  3. $6.0bn
  4. $6.6bn
  5. $6.5bn

Net earnings

Net earnings by quarter
  1. $0.9bn
  2. $0.8bn
  3. $0.7bn
  4. $1.3bn
  5. $0.8bn

The business split for Q3 2025 is Stryker’s restated figure. Adjusted figures leave out one-off charges. Stryker Q3 2026 results, 29 Oct 2026

Products and progress

Where each Stryker product has got to, from first announcement to widely available. Checked against Stryker’s Q3 2026 results (29 Oct 2026) and its announcements.

Robots

  1. Mako robotic surgery Widely available

    Over 2.5 million Mako operations in 47 countries (Jul 2026)

    A robotic arm that helps surgeons fit knee and hip replacements to a 3D plan of the patient. Mako 4 is the latest model. Stryker news, 16 Jul 2026

  2. Mako RPS handheld robot Early rollout

    Full US launch 16 Jul 2026, after a limited launch in Feb 2026

    A handheld robotic saw for knee replacements that keeps each cut on the plan, with no cutting blocks needed. Stryker news, 16 Jul 2026

  3. Mako Shoulder Early rollout

    Full market release (Mar 2026); coming to Mako 4 in the second half of 2026

    Mako for reverse shoulder replacements, with Tornier implants and Blueprint planning software. Stryker news, 3 Mar 2026

Joints

  1. Triathlon Gold knee Early rollout

    Launched Mar 2026

    A 3D-printed knee part with a gold-coloured titanium nitride coating, for patients sensitive to some metals. Stryker news, 3 Mar 2026

  2. Incompass ankle replacement Early rollout

    Prophecy planning now available with it (16 Sep 2026)

    A total ankle replacement. Prophecy plans each operation from the patient’s own scans. Stryker news, 16 Sep 2026

  3. FiberLocker rotator cuff repair Early rollout

    Stryker completed buying its maker, ZuriMED, 26 Oct 2026

    Strengthens the stitching when a torn shoulder tendon is repaired. Stryker news, 26 Oct 2026

Instruments

  1. New surgical power tools Early rollout

    TPX HD and BPX cordless tools introduced Mar 2026

    Drills and saws for joint revision, trauma, foot and ankle and hand surgery. Stryker news, 3 Mar 2026

Vascular

  1. Clot removal (Inari) Widely available

    Vascular sales of $566m in Jul–Sep 2026, up 8%

    FlowTriever and ClotTriever pull large blood clots out of veins and lungs. Stryker bought Inari for $4.9bn in Feb 2025. Stryker Q3 2026 results

  2. Pulse lithotripsy (Amplitude Vascular) Testing

    Bought May 2026; US trials under way

    A balloon that sends pressure waves to crack hard calcium inside narrowed arteries so they can be opened. MedTech Dive, 8 May 2026

Hospital

  1. Endoscopy Widely available

    $1.02bn of sales in Jul–Sep 2026, up 14%

    Cameras, lights and tools for keyhole surgery, and kit for operating theatres. Stryker Q3 2026 results

  2. Medical (beds, defibrillators) Widely available

    $1.08bn of sales in Jul–Sep 2026, up 10%

    Hospital beds, stretchers, emergency care equipment and LIFEPAK defibrillators. Stryker Q3 2026 results

  3. Neuro Cranial Widely available

    $670m of sales in Jul–Sep 2026, up 5%

    Tools and implants for brain and skull surgery, now part of the Instruments business. Stryker Q3 2026 results

What’s new

  1. Filing Ronda E Stryker: sold 550,000 shares ($179m) SEC,
  2. Filing Company announcement: board or management change, statement to investors SEC,
  3. Filing Notice of a planned share sale SEC,
  4. Filing Quarterly report SEC,
  5. News Stryker lowers 2026 guidance after slowdown in hip, knee procedures MedTech Dive,
  6. Filing Company announcement: results or delivery report SEC,

The last 30 days. Headlines link to the full stories on the publishers’ own sites.

Numbers

Sales each quarter

Stryker sales each quarter
  1. $7bn

Net profit each quarter

Stryker net profit each quarter
  1. $1bn
QuarterMonthsSalesNet profit
Q3 2026Jul–Sep 2026 $6.52bn $753m
Q2 2026Apr–Jun 2026 $6.59bn $1.28bn
Q1 2026Jan–Mar 2026 $6.02bn $745m
Q4 2025Oct–Dec 2025 $7.17bn $849m
Q3 2025Jul–Sep 2025 $6.06bn $859m
Q2 2025Apr–Jun 2025 $6.02bn $884m
Q1 2025Jan–Mar 2025 $5.87bn $654m

From Stryker’s results filed with the SEC; newer quarters appear automatically, with the business split added after each report is checked.

Medical device safety

Stryker’s product recalls and the problem reports that hospitals, doctors, patients and Stryker itself send to the US Food and Drug Administration (FDA).

Products recalled, last 12 months530 in the most serious class
Problem reports, last 12 months8,50329 deaths and 2,889 injuries reported
Products recalled since records began1,045FDA online records start in 2012

Products recalled each year

Recalls each year
  1. 53

Problem reports each month

Device problem reports each month
  1. 899

Latest recalls

  • Class IIPrecision Pointer Electromagnetic (8000-050-001) 24 Sep 2026 · Ongoing
    Why

    Device may fracture during use at the laser welded joint on the pointer tube. If this happens, loose parts may fall out of the product while the device is inside the patient.

  • Class IIREF:2B5ST Ethicon Endo-Surgery, Inc. XCEL BLADELESS TROCAR W/OPTIVIEW TECHNOLOGY & SLEEVE 5MM X 75MM 19 Aug 2026 · and 5 more products · Ongoing
    Why

    Reusable access port system may crack or seperate during use.

  • Class IIBARD EP XT DECAPOLAR STEERABLE, DIAGNOSTIC EP CATHETER, 6F, LARGE 4.0, 10, 2-5-2MM, REF: 201007 18 Aug 2026 · Ongoing
    Why

    Diagnostic electrophysiology (EP) catheter may have a breached sterile barrier on the straight seal side of the primary pouch, which if used could lead to particulate embolization, infection, thrombus or ganuloma formation from particulate matter.

  • Class IIStryker Hoffmann II Connecting Rod Micro 3 x 40mm. Catalog Number: 50796040. 1 Jul 2026 · and 6 more products · Ongoing
    Why

    Potential cracking of the Hoffmann II Carbon Connecting Rods following cleaning and sterilization.

  • Class IISTRYKER AHTO DUAL SPIKE TUBE SET PACKAGING, Catalog Number 0250070640 8 Jun 2026 · and 4 more products · Ongoing
    Why

    There has been an increased amount in reported complaints consistently describing leaking from the handpiece during use.

  • Class IINeptune Smart Docking Station (120V), Catalog Number 0770-100-000, part of the Neptune Waste Management System 6 May 2026 · Ongoing
    Why

    It has been identified that the impacted docking station (SN 2521008873) was not product released from manufacturing and may not have completed required testing prior to being shipped to your facility. There is a potential risk of electrical shock due to the device s safety testing being unverifiable.

Each product counts once, so one recall can cover several. Problem reports come from hospitals, doctors, patients and makers; a report does not prove the device caused the problem. From the FDA’s openFDA records, read every week.

Directors’ share deals

Directors and senior staff must tell the SEC within two business days when they buy, sell or are given shares.

ReportedWhoWhat happened
9 Nov 2026 Ronda E StrykerDirector Sold 550,000 shares at $325.32 ($179m)
28 Sep 2026 Preston Wendell WellsVP, Chief Financial Officer Other 109 shares
24 Sep 2026 Preston Wendell WellsVP, Chief Financial Officer Other 2,739 shares
2 Sep 2026 Mary K BrainerdDirector Bought 131 shares at $204.09 ($26,736)
26 Aug 2026 Dylan Bram CrottyGroup President Sold 441 shares at $328.61 ($144,915)
20 Aug 2026 Ronda E StrykerDirector Sold 350,000 shares at $336.50 ($118m)
18 Aug 2026 Debra KingSee Remarks Sold 826 shares at $336.30 ($277,787)
4 Aug 2026 Kimberly Ann MontagninoVP, Chief Comm. Officer Shares kept back for tax 155 shares

From Form 4 filings on SEC EDGAR. ‘Used options’ means turning share options into shares; it is not a purchase on the market.

Short sellers

Short sellers borrow shares and sell them, hoping to buy them back cheaper later. More shares sold short means more traders are betting the price will fall.

Shares sold short on 30 Oct6.7m1.7% of all Stryker shares
Days to cover2.2Days of normal trading it would take to buy them all back
Change since 15 Oct+1.0mUp 16.8%

Shares sold short, twice a month

Shares sold short
  1. 6.7m

From FINRA, the US regulator for brokers. Figures are for the middle and end of each month and come out about a week later. Total shares from Stryker’s latest SEC filing (380,691,004). Read every morning.

Chart by TradingView. Prices may be delayed. This page is not investment advice.

Timeline

  1. Jan 2027Spencer Stiles becomes chief executive.
  2. Jul 2026Fully launches the Mako RPS handheld robot in the US.
  3. Feb 2025Completes the $4.9bn purchase of Inari Medical.
  4. Dec 2013Buys MAKO Surgical, maker of the Mako robot.
  5. 1941Dr Homer Stryker starts the company in Kalamazoo, Michigan.

On X

Posts worth seeing will be added here. Meanwhile, these are the accounts to follow:

What do you think?

Share your view on Stryker with other ChartsView members.

Start a Stryker thread on the forum

Where this comes from

All sources are free and public. Data is collected each morning and refreshed through the day. This page is for information only and is not investment advice.

ChartsView is independent and is not connected with, or endorsed by, Stryker Corporation. The company’s name is used only to say who this page is about.

Use the arrow keys to move and Enter to openSearch every page

Share tips